PATENT CLAIM ANALYSIS

Application Number: 16284456
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-09
Patent Classification: ["424", "465000"]

Abstract:
The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Claim (Index 15):
The composition according to  claim 14  wherein said composition is in the form of a tablet or capsule.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 99.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10440404', '10830071', '12205769', '11216904', '15491870']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7160760890892172
- 35 USC 102 Novelty (BERT): 0.5562752785164264
- Combined Prediction Score: 0.700096008031938
- Mean Citation Score: 236.47558400000003
- Max Citation Score: 284.21927
- Similarity Product: 184.42935130513192

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test